Background: Postoperative liver regeneration is essential for maintaining hepatic function. This study evaluated the rate, determinants, and volumetric patterns of early liver regeneration after hemihepatectomy. Methods: A retrospective review was conducted of 50 patients who underwent right or left hemihepatectomy between April 2019 and March 2025. Liver and spleen volumes (SV) were assessed preoperatively, at postoperative day (POD) 1 week, and at POD 3 months. Early liver regeneration rate (LRR) was defined as the percentage increase in remnant liver volume at POD 1 week relative to the preoperative future liver remnant (FLR), and patients were categorized into low (<50%) and high (≥50%) LRR groups. Clinical, biochemical, and volumetric variables were compared, and predictors of regeneration were identified using multivariable analyses. Regeneration patterns were also examined according to whether the FLR/standard liver volume (SLV) ratio was <50% or ≥50%. Results: FLR/SLV was the strongest independent predictor of rapid early liver regeneration (p<0.001). Remnants with FLR/SLV <50% exhibited rapid and sustained regeneration, whereas those with FLR/SLV ≥50% showed slower regrowth that plateaued after reaching approximately 90% of SLV. SV increased at POD 1 week in all patients; however, only the FLR/SLV ≥50% group showed a reduction by POD 3 months, whereas the <50% group maintained elevated volumes. Conclusions FLR/SLV reliably predicts early postoperative liver regeneration. Smaller remnants regenerate more rapidly, whereas persistent splenic enlargement suggests a sustained portal hemodynamic burden. Combined evaluation of FLR/SLV and SV may enhance perioperative risk assessment and surgical planning.

Background: Platelet-rich plasma (PRP) has been proposed to enhance liver regeneration, but its effects remain inconsistent across experimental models. This study evaluated whether autologous PRP promotes hepatic regeneration after major hepatectomy in rabbits and assessed the feasibility of this experimental approach. Methods: Twenty-one male New Zealand white rabbits underwent major hepatectomy and received saline (control) or PRP via portal vein or subcutaneous injection. Survival, pre- and postoperative laboratory results, regenerated liver weight, biochemical markers, and histologic features were compared. Results: Overall survival was 42%. Portal vein injection resulted in significantly higher mortality than subcutaneous injection (66% vs. 33%; p=0.050). Regenerated liver weight (approximately 60–70 g) and the graft-to-body weight ratio did not differ between groups. One PRP-treated rabbit demonstrated pronounced hepatic plate thickening, but overall regenerative markers showed no significant benefit. PRP preparations displayed variable leukocyte content. Conclusions PRP did not provide a measurable regenerative advantage in this rabbit major hepatectomy model. The high mortality and heterogeneous PRP composition emphasize the need for safer experimental designs and standardized PRP preparations to accurately assess its regenerative capacity.

Although gemcitabine-based regimens are widely used as an effective treatment for pancreatic cancer, acquired resistance to gemcitabine has become an increasingly common problem. Therefore, a novel therapeutic strategy to treat gemcitabine-resistant pancreatic cancer is urgently required. Piceamycin has been reported to exhibit antiproliferative activity against various cancer cells; however, its underlying molecular mechanism for anticancer activity in pancreatic cancer cells remains unexplored. Therefore, the present study evaluated the antiproliferation activity of piceamycin in a gemcitabine-resistant pancreatic cancer cell line and patient-derived pancreatic cancer organoids. Piceamycin effectively inhibited the proliferation and suppressed the expression of alpha-actinin-4, a gene that plays a pivotal role in tumorigenesis and metastasis of various cancers, in gemcitabine-resistant cells. Long-term exposure to piceamycin induced cell cycle arrest at the G0/G1 phase and caused apoptosis. Piceamycin alsoinhibited the invasion and migration of gemcitabine-resistant cells by modulating focal adhesion and epithelial-mesenchymal transition biomarkers. Moreover, the combination of piceamycin and gemcitabine exhibited a synergistic antiproliferative activity in gemcitabine-resistant cells. Piceamycin also effectively inhibited patient-derived pancreatic cancer organoid growth and induced apoptosis in the organoids. Taken together, these findings demonstrate that piceamycin may be an effective agent for overcoming gemcitabine resistance in pancreatic cancer.

This report presents the latest statistics on the stroke population in South Korea, sourced from the Clinical Research Collaborations for Stroke in Korea-National Institute for Health (CRCS-K-NIH), a comprehensive, nationwide, multicenter stroke registry. The Korean cohort, unlike western populations, shows a male-to-female ratio of 1.5, attributed to lower risk factors in Korean women. The average ages for men and women are 67 and 73 years, respectively.Hypertension is the most common risk factor (67%), consistent with global trends, but there is a higher prevalence of diabetes (35%) and smoking (21%). The prevalence of atrial fibrillation (19%) is lower than in western populations, suggesting effective prevention strategies in the general population. A high incidence of large artery atherosclerosis (38%) is observed, likely due to prevalent intracranial arterial disease in East Asians and advanced imaging techniques.There has been a decrease in intravenous thrombolysis rates, from 12% in 2017–2019 to 10% in 2021, with no improvements in door-to-needle and door-to-puncture times, worsened by the coronavirus disease 2019 pandemic. While the use of aspirin plus clopidogrel for noncardioembolic stroke and direct oral anticoagulants for atrial fibrillation is well-established, the application of direct oral anticoagulants for non-atrial fibrillation cardioembolic strokes in the acute phase requires further research. The incidence of early neurological deterioration (13%) and the cumulative incidence of recurrent stroke at 3 months (3%) align with global figures. Favorable outcomes at 3 months (63%) are comparable internationally, yet the lack of improvement in dependency at 3 months highlights the need for advancements in acute stroke care.

Objective: Early identification of patients at risk for deterioration is crucial to reduce in-hospital mortality. Various early warning scores have been widely applied in the emergency department (ED) of hospitals. This study evaluates and compares the effectiveness of three early warning scores_Modified Early Warning Score, Rapid Acute Physiology Score (RAPS), Worthing Physiological Scoring System (WPS), and Rapid Emergency Medicine Score. These scores help predict the need for critical care and 24- and 72-hour mortalities among alert patients presenting to the ED with dyspnea. Methods: This retrospective cohort study used data from electronic medical records of patients admitted between 2018 and 2020 and included all consecutive alert patients who presented with dyspnea in the ED. The primary outcome was to evaluate the performance of early warning scores regarding the need for critical care. The secondary outcomes were the prediction of 24- and 72-hour in-hospital mortalities. Results: Among 4,322 patients evaluated, 255 received critical care, and 17 and 84 died within 24 and 72 hours, respectively. The WPS had the overall highest performance for predicting the need for critical care (area under the curve [AUC], 0.781; 95% confidence interval [CI], 0.751-0.810) and 24-hour (AUC, 0.816; 95% CI, 0.738-0.894) and 72-hour mortalities (AUC, 0.794; 95% CI, 0.750-0.838), but differed significantly only from the RAPS. Conclusion The WPS might better predict the need for critical care and short-term mortality in alert patients with dyspnea in the ED. However, owing to a lack of its superiority in statistics, further studies are warranted to conclude the optimal tools applicable for these patients.

BACKGROUND: Three-dimensional (3D) printing using hydrogel has made great strides when it comes to mimicking 3Dartificial tissue in the medical field. However, most structures do not mimic the dynamic movement of the tissues. Withoutimitating dynamic movements, there are limitations on the extent to which the proper implementation of the tissue’s ownfunctions can be achieved.METHOD: In this study, we intend to present an approach to solving this problem using hydroxybutyl methacrylatedchitosan (HBC-MA), a photo-crosslinkable/temperature reversible chitosan polymer. In addition, stereolithography-3D(SLA-3D) printing technology was used, which is more likely to mimic the complex microstructure. As a control, a 3Dstructure made with pristine poly(ethylene glycol) dimethacrylate (PEG-DMA) was created, and a 4D structure wasprepared by adding HBC-MA to poly(ethylene glycol) dimethacrylate (PEG-DMAP) resin. RESULTS: HBC-MA caused the expansion of water into the polymer matrix at low temperature, and the 4D structureresulted in expansion of the polymer volume, generating dynamic movement due to the expansion of water. Conversely, asthe temperature rose, deswelling occurred, followed by a decrease in the volume, showing a shape memory property ofreturning to the existing structure. Morphological, swelling, and mechanical analysis further confirmed the principle ofdynamic movement. In addition, parameters were provided through calculation of the bending ratio angle (h). CONCLUSION Through this, it is suggested that HBC-MA can be applied as a core polymer for SLA-4D printing, andhas high potential for realizing the dynamic movement of tissue.

BACKGROUND: Three-dimensional (3D) printing using hydrogel has made great strides when it comes to mimicking 3Dartificial tissue in the medical field. However, most structures do not mimic the dynamic movement of the tissues. Withoutimitating dynamic movements, there are limitations on the extent to which the proper implementation of the tissue’s ownfunctions can be achieved.METHOD: In this study, we intend to present an approach to solving this problem using hydroxybutyl methacrylatedchitosan (HBC-MA), a photo-crosslinkable/temperature reversible chitosan polymer. In addition, stereolithography-3D(SLA-3D) printing technology was used, which is more likely to mimic the complex microstructure. As a control, a 3Dstructure made with pristine poly(ethylene glycol) dimethacrylate (PEG-DMA) was created, and a 4D structure wasprepared by adding HBC-MA to poly(ethylene glycol) dimethacrylate (PEG-DMAP) resin. RESULTS: HBC-MA caused the expansion of water into the polymer matrix at low temperature, and the 4D structureresulted in expansion of the polymer volume, generating dynamic movement due to the expansion of water. Conversely, asthe temperature rose, deswelling occurred, followed by a decrease in the volume, showing a shape memory property ofreturning to the existing structure. Morphological, swelling, and mechanical analysis further confirmed the principle ofdynamic movement. In addition, parameters were provided through calculation of the bending ratio angle (h). CONCLUSION Through this, it is suggested that HBC-MA can be applied as a core polymer for SLA-4D printing, andhas high potential for realizing the dynamic movement of tissue.

Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH deficiency. This position statement is based on a systematic review of evidence and expert opinions.

Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.
Acromegaly ; Expert Testimony ; Growth Hormone ; Humans ; Octreotide ; Pituitary Neoplasms ; Somatostatin